30Jan 2017

RESVERATROL AS AN ALTERNATIVE TO REGULAR BLOOD TRANSFUSION- A NEW FETAL HAEMOGLOBIN INDUCER FROM NATURAL WORLD

  • Department of Genetics, Institute of Genetic Medicine and Genomic Science. 30A Thakurhat Road. Kolkata- 700128, West Bengal, India.
  • Department of Genetics, Institute of Genetic Engineering. 30 Thakurhat Road. Kolkata- 700128, West Bengal India.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Recent molecular studies of fetal hemoglobin (HbF) regulation have shown promise for the development of clinical HbF inducers to be used in patients with β-thalassemia and sickle cell disease. However, while numerous promising inducers of HbF, have been studied at past in β-thalassemia patient with limited success resulted no universally effective agents. Increased production of fetal hemoglobin (HbF) can ameliorate the severity of both β-thalassemia and sickle cell disease (SCD), the major disorders of β-hemoglobin. The defective production of the β-globin molecule in patients with β-thalassemia can be compensated for by an increase in the production of the β-like globin molecule, γ-globin, which pairs together with α-globin chains to form HbF. Here we examined the clinical studies of one HbF inducer Trans-Resveratrol and found Complete Response (52.2%), Partial Response (18.2%) and Non response (15.9%) in patients who, after more than one year of treatment, remained at the different level of transfusion dependency with extended transfusion intervals. The present study is to provide a resource that will be valuable for the design of future studies of HbF inducers in β-thalassemia. According to our knowledge and literature review, probably this could be the first report for resveratrol clinical trial in eastern Indian population.


  1. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem. 1997;30(2):91-113.? (PubMed)
  2. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783-2840.? (PubMed)
  3. Romero-Perez AI, Ibern-Gomez M, Lamuela-Raventos RM, de La Torre-Boronat MC. Piceid, the major resveratrol derivative in grape juices. J Agric Food Chem. 1999;47(4):1533-1536. ?(PubMed)
  4. Siemann EH, Creasey LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic. 1992;43(1):49-52.
  5. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275(5297):218-220.? (PubMed)
  6. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191-196.? (PubMed)
  7. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. Cambridge, UK: Cambridge University Press, 2001.
  8. Thein SL. Genetic insights into the clinical diversity of beta thalassaemia. Br J Haematol 2004;124:264?74.
  9. Old JM. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev 2003;17:43?53.
  10. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005;49(5):472-481.? (PubMed)
  11. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003;36(1):79-87. ?(PubMed)
  12. Lo L, Singer ST. Thalassemia: current approach to an old disease. Pediatr Clin North Am 2002;49:1165?91.
  13. Olivieri NF. Reactivation of fetal hemoglobin in patients with betathalassemia. Semin Hematol 1996;33:24?42.
  14. . Olivieri NF, Rees DC, Ginder GD, Thein SL, Waye JS, Chang L, et al. Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley?s anemia. Ann N Y Acad Sci 1998;850:100?9.
  15. Cao H. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors. Hematology 2004;9:223?33.
  16. Lo L, Singer ST. Thalassemia: current approach to an old disease. Pediatr Clin North Am 2002;49:1165?91.
  17. Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol 2001;38:367?73.
  18. Olivieri NF, Weatherall DJ. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet 1998;7:1655?8.
  19. Wang HX, Ng TB. Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities. Life Sci 1999;65:2663?77.
  20. Cle`ment MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998;92:996?1002.
  21. Nicoletta Bianchi, Cristina Zuccato, Ilaria Lampronti, Monica Borgatti and Roberto Gambari. Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of β-Thalassemia and Sickle-Cell Anemia. Advance Access Publication 11 December 2007 & eCAM 2009;6(2)141?151.

[Anirban Roy Chowdhury, Puspal De, Sudipa Chakravarty and Amit Chakravarty. (2017); RESVERATROL AS AN ALTERNATIVE TO REGULAR BLOOD TRANSFUSION- A NEW FETAL HAEMOGLOBIN INDUCER FROM NATURAL WORLD Int. J. of Adv. Res. 5 (1). 1816-1821] (ISSN 2320-5407). www.journalijar.com


Puspal De
Institute of Genetic Engineering

DOI:


Article DOI: 10.21474/IJAR01/2950       DOI URL: http://dx.doi.org/10.21474/IJAR01/2950


Share this article